Literature DB >> 21399606

Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.

M Tafaghodi1, M Eskandari, M Kharazizadeh, A Khamesipour, M R Jaafari.   

Abstract

Immune responses against the Leishmania antigens are not sufficient to protect against a leishmania challenge. Therefore these antigens need to be potentiated by various adjuvants and delivery systems. In this study, Poly (d,l-lactide-co-glycolide (PLGA) nanospheres as antigen delivery system and Quillaja saponins (QS) as immunoadjuvant have been used to enhance the immune response against autoclaved Leishmania major (ALM). PLGA nanospheres were prepared by a double-emulsion (W/O/W) technique. Particulate characteristics were studied by scanning electron microscopy and particle size analysis. Mean diameter for nanospheres loaded with ALM+QS was 294 ± 106 nm. BALB/c mice were immunized three times in 3-weeks intervals using ALM plus QS loaded nanospheres [(ALM+QS)PLGA], ALM encapsulated with PLGA nanospheres [(ALM)PLGA], (ALM)PLGA + QS, ALM + QS, ALM alone or PBS. The intensity of infection induced by L. major challenge was assessed by measuring size of footpad swelling. The strongest protection, showed by significantly (P < 0.05) smaller footpad, were observed in mice immunized with (ALM)PLGA. The (ALM+QS)PLGA group showed the least protection and highest swelling, while the (ALM)PLGA+QS, ALM+QS and ALM showed an intermediate protection with no significant difference. The mice immunized with ALM and ALM+QS showed the highest IgG2a/IgG1 ratio (P < 0.01), followed by (ALM)PLGA+QS. The highest IFN-γ and lowest IL-4 production was seen in (ALM)PLGA+QS, ALM+QS groups. The highest parasite burden was observed in (ALM)PLGA+QS and (ALM+QS)PLGA groups. It is concluded that PLGA nanospheres as a vaccine delivery system could increase the protective immune responses, but QS adjuvant has a reverse effect on protective immune responses and the least protective responses were seen in the presence of this adjuvant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21399606

Source DB:  PubMed          Journal:  Trop Biomed        ISSN: 0127-5720            Impact factor:   0.623


  9 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.

Authors:  Ankita Thakur; Harpreet Kaur; Sukhbir Kaur
Journal:  Med Microbiol Immunol       Date:  2014-11-29       Impact factor: 3.402

3.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

4.  The efficacy of hydro alcoholic extract of Seidlitzia rosmarinus on experimental zoonotic cutaneous leishmaniasis lesions in murine model.

Authors:  Maryam Ahmadi; Abdolmajid Fata; Ali Khamesipour; Hasan Rakhshandeh; Akram Miramin Mohammadi; Ghodratollah Salehi; Hadi Monavari
Journal:  Avicenna J Phytomed       Date:  2014-11

5.  Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin.

Authors:  Maryam Mohajer; Bahman Khameneh; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2014-09       Impact factor: 2.699

Review 6.  Medicinal plants with promising antileishmanial activity in Iran: a systematic review and meta-analysis.

Authors:  Masoud Soosaraei; Mahdi Fakhar; Saeed Hosseini Teshnizi; Hajar Ziaei Hezarjaribi; Elham Sadat Banimostafavi
Journal:  Ann Med Surg (Lond)       Date:  2017-07-27

7.  Formulation and Optimization of a New Cationic Lipid-Modified PLGA Nanoparticle as Delivery System for Mycobacterium tuberculosis HspX/EsxS Fusion Protein: An Experimental Design.

Authors:  Farzad Khademi; Arshid Yousefi-Avarvand; Mohammad Derakhshan; Mohammad Reza Abbaspour; Kayvan Sadri; Mohsen Tafaghodi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

8.  Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration.

Authors:  Farzad Khademi; Arshid Yousefi; Mohammad Derakhshan; Adel Najafi; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2019-08       Impact factor: 2.699

9.  Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis.

Authors:  Maritsa Margaroni; Maria Agallou; Evita Athanasiou; Olga Kammona; Costas Kiparissides; Catherine Gaitanaki; Evdokia Karagouni
Journal:  Int J Nanomedicine       Date:  2017-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.